Effects of Three Kinds of Chinese Medicine Polysaccharides on the Immune Effect of Newcastle Disease Vaccine

240 14-day-old healthy and non-immune Roman chicken were randomly divided into 8 groups, including blank control group （BC group）, immune control group （IC group）, and immunity groups of each Chinese medicine. On the day of the first immunity, 3 d before the second immunity, the day of the second immunity and 3 d after the second immunity, high-dose concentration and low-dose concen- tration of Astragalus polysaccharide （ASP）, Epimedium polysaccharide （EPP） and Isatis roots polysaccharide （IRPS） were used for the immunity groups of each Chi- nese medicine using the gavage, and 0.5 ml for each chick, and the equivalent normal saline was used for the blank control group and vaccine control group. On the 7^th, 14^th, 21^st and 28^th day after the first immunity, 10 chicken of each group were randomly got and weighed, and the antibody titer and the changes of the pro- liferation of T lymphocyte were measured. The results showed that 3 kinds of Chi- nese medicine polysaccharides all can increase the weight of chicken, improve HI antibody titer of Newcastle disease, and promote the proliferation of peripheral T lymphocyte, in which the effect of IRPS at low dosage is the best.

Effect of difference doses of Newcastle disease vaccine immunization on growth performance,plasma variables and immune response of broilers

Background： As a member of the Paromyxoviridoe group, Newcastle disease virus （NDV） is the key causative agent of Newcastle disease （ND） that attacks chickens, turkeys and other avian birds. Surviving birds showed lower feed utilization, growth performance or egg production, which results in severe economic losses. The purpose of this study was to determine the effect of different doses of NDV immunization on growth performance, plasma variables and immune response of broiler chickens. Methods： A total of 480 one-day-old Arbor Acres broilers were randomly administrated with 0, 4, 6 or 8 doses of NDV at 12 d and 28 d, respectively. Each group consisted of ten replicates with 12 birds each. Growth performance and organ weight were recorded. Plasma concentration of glucose, total protein, cholesterol, triglycerides and nonesterified fatty acid was determined using commercial kits. The concentration of plasma corticosterone and insulin was measured using commercially available radio immune assay kits. Serum antibody titer and peripheral blood lymphocyte proliferation were also recorded. Results： The results showed that NDV decreased body weight gain （BWG）, and increased Feed：Gain ratio at 1-2 ] d at all doses （P 〈 0.05）. Plasma insulin concentration was lower in all immunization groups after the first immunization at 12 d （P 〈 0.01）. The rest of the plasma indexes were not affected by NDV immunization, including glucose, total protein, cholesterol, triglycerides, nonesterified fatty acid, heterophil/lymphocyte ratio, as well as the proliferation of peripheral blood lymphocyte （P 〉 0.05）. Compared with the control group, NDVtreatment elevated NDV antibody titer at 10 d after the first inoculation （P 〈 0.05）, and at d 5, 9 and 13 after the second inoculation （P 〈 0.05）. Repeated NDV inoculation had no deleterious impacts on body composition at 42 d, and nutrient accretion rates at 8-42 d （P 〉 0.05）. Conclusions： In conclusion, NDV challenge decreased BWG and feed efficiency in earlier stage of growth. However NDV treatment at 6 doses down-regulated the Feed：Gain ratio by 6.36 % throughout the whole growing period. These data suggest that appropriate lower doses of NDV inoculation increase feed efficiency of broiler chickens.

Feasibility Study of Aluminum Hydroxide Sol as Adjuvant to Prepare Stable Vaccine Using Newcastle Disease Virus as a Model

Aluminum hydroxide sol （consisting of aluminum hydroxide nano-particles） prepared by a hydrothermal method was used as nano-aluminum adjuvant adsorbed the inactived Newcastle disease virus （NDV）. The zeta potential of aluminum hydroxide colloidal particles,the inactivated NDV and the nano-aluminum adjuvant NDV are ＋48.16 mV,？13.8 mV and ＋39.97 mV,respec-tively. The nano-aluminum adjuvant vaccine was transparent and stable without precipitate,whereas the conventional aluminum ad-juvant vaccine was turbid and a white precipitate was visible soon. The hemagglutination inhibition （HI） titers of the nano-aluminum adjuvant group were generally higher than those of the conventional aluminum group except the titer on day 29. The results show that the nano-aluminum adjuvant has better stability and higher levels of antibodies for a longer time than the conventional aluminum adjuvant.

Longest survival with primary intracranial malignant melanoma:A case report and literature review

BACKGROUND Primary intracranial malignant melanoma(PIMM)is rare,and its prognosis is very poor.It is not clear what systematic treatment strategy can achieve long-term survival.This case study attempted to identify the optimal strategy for long-term survival outcomes by reviewing the PIMM patient with the longest survival following comprehensive treatment and by reviewing the related literature.CASE SUMMARY The patient is a 47-year-old Chinese man who suffered from dizziness and gait disturbance.He underwent surgery for right cerebellum melanoma and was subsequently diagnosed by pathology in June 2000.After the surgery,the patient received three cycles of chemotherapy but relapsed locally within 4 mo.Following the second surgery for total tumor resection,the patient received an injection of Newcastle disease virus-modified tumor vaccine,interferon,andβ-elemene treatment.The patient was tumor-free with a normal life for 21 years before the onset of the recurrence of melanoma without any symptoms in July 2021.A third gross-total resection with adjuvant radiotherapy and temozolomide therapy was performed.Brain magnetic resonance imaging showed no residual tumor or recurrence 3 mo after the 3rd operation,and the patient recovered well without neurological dysfunction until the last follow-up in June 2022,which was 22 years following the initial treatment.CONCLUSION It is important for patients with PIMM to receive comprehensive treatment to enable the application of the most appropriate treatment strategies.Long-term survival is not impossible in patients with these malignancies.